0001213900-24-025771.txt : 20240326 0001213900-24-025771.hdr.sgml : 20240326 20240326080002 ACCESSION NUMBER: 0001213900-24-025771 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240326 FILED AS OF DATE: 20240326 DATE AS OF CHANGE: 20240326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALTERITY THERAPEUTICS LTD CENTRAL INDEX KEY: 0001131343 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-49843 FILM NUMBER: 24780955 BUSINESS ADDRESS: STREET 1: LEVEL 3, 460 BOURKE STREET CITY: MELBOURNE STATE: C3 ZIP: VIC 3000 BUSINESS PHONE: 61 3 9349 4906 MAIL ADDRESS: STREET 1: LEVEL 3, 460 BOURKE STREET CITY: MELBOURNE STATE: C3 ZIP: VIC 3000 FORMER COMPANY: FORMER CONFORMED NAME: PRANA BIOTECHNOLOGY LTD DATE OF NAME CHANGE: 20010105 6-K 1 ea0202565-6k_alterity.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of March 2024

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒     Form 40-F  ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1  Alterity Receives a $3.9 million R&D Tax Incentive Refund

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Alterity Therapeutics Limited
   
  By:  /s/ Geoffrey P. Kempler
    Geoffrey P. Kempler
    Chairman

 

Date: March 26, 2024

 

 

2

 

 EX-99.1 2 ea020256501ex99-1_alterity.htm ALTERITY RECEIVES A $3.9 MILLION R&D TAX INCENTIVE REFUND

Exhibit 99.1

 

 

 

Alterity Therapeutics Receives a $3.9 million
Research & Development Tax Incentive Refund

 

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 26 March 2024. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme.

 

The cash refund relates to the cost of eligible research and development activities conducted during the financial year ended 30 June 2023, and represents the amount disclosed in the company’s audited financial statements. These funds will be used to further Alterity’s Phase 2 clinical trials in MSA, ATH434- 201 and ATH434-202, along with planning for a potential Phase 3 clinical trial in MSA, continuing discovery and research efforts in neurodegenerative diseases, including Parkinson’s Disease, and general working capital.

 

About ATH434

 

Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early- stage MSA and Study ATH434-202 is an open-label Phase 2 Biomarker trial in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the U.S. FDA and the European Commission.

 

About Alterity Therapeutics Limited

 

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.

 

Authorisation & Additional information

 

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

 

 

 

 

Investor and Media Contacts:

 

Australia

 

Hannah Howlett

we-aualteritytherapeutics@we-worldwide.com

+61 450 648 064

 

U.S.

 

Remy Bernarda

remy.bernarda@iradvisory.com

+1 (415) 203-6386

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end